Connection
Kalie Tommerdahl to Hypoglycemic Agents
This is a "connection" page, showing publications Kalie Tommerdahl has written about Hypoglycemic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.378 |
|
|
|
-
Tommerdahl KL, Kendrick J, Bjornstad P. The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial. Clin J Am Soc Nephrol. 2022 06; 17(6):905-907.
Score: 0.118
-
Tommerdahl KL, Nelson RG, Bjornstad P. Dapagliflozin in young people with type 2 diabetes. Lancet Diabetes Endocrinol. 2022 05; 10(5):303-304.
Score: 0.118
-
Tommerdahl KL, Nadeau KJ, Bjornstad P. Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists. Adv Chronic Kidney Dis. 2021 07; 28(4):337-346.
Score: 0.112
-
Pauley ME, Tommerdahl KL, Snell-Bergeon JK, Forlenza GP. Continuous Glucose Monitor, Insulin Pump, and Automated Insulin Delivery Therapies for Type 1 Diabetes: An Update on Potential for Cardiovascular Benefits. Curr Cardiol Rep. 2022 12; 24(12):2043-2056.
Score: 0.031